Losartan Potassium Tablet, Film Coated
Product Images NDC 72789-282

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72789-282). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image001 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 01)

Chemical structure of losartan potassium, showing its molecular arrangement including chlorine, hydroxyl, and potassium ions.*

FDA Label Image

Image002 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 02)

A line graph comparing the percentage of patients with the primary endpoint over study months for Atenolol (dotted line) and Losartan potassium (solid line). The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients from 0 to 16. An annotation notes an adjusted risk reduction of 13% with p=0.021.*

FDA Label Image

Image003 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 03)

A line graph comparing percentage of patients with fatal/non-fatal stroke over a study period of up to 66 months for Atenolol and Losartan potassium. Atenolol is represented by a dotted line, Losartan potassium by a solid line, showing a lower cumulative percentage for Losartan potassium. The graph includes an adjusted risk reduction of 25% with p=0.001.*

FDA Label Image

Image004 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 04)

A forest plot comparing the event rates and hazard ratios with 95% confidence intervals for Losartan Potassium versus Atenolol across various patient subgroups in a clinical study. The plot includes data for primary composite endpoints and stroke (fatal/non-fatal) events, stratified by age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). Hazard ratios indicate relative favorability toward Losartan Potassium or Atenolol.*

FDA Label Image

Image005 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 05)

A line graph showing the percentage of patients with an event over 48 months, comparing Losartan potassium to placebo. The graph includes a solid line for Losartan potassium and a dotted line for placebo, with a noted risk reduction of 16.1% and a p-value of 0.022.*

FDA Label Image

72789282 Label (72789282)

Label for Losartan Potassium USP 25 mg film-coated tablets by PD-Rx Pharmaceuticals, Inc. The label shows the product name, strength, quantity of 30 tablets, NDC 72789-282-30, and manufacturer information from Oklahoma City, OK. It includes dosage instructions space, warnings to keep out of reach of children, and expiration date 12/2023, lot J22C10.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.